394 related articles for article (PubMed ID: 36547823)
1. A Review on Advanced CRISPR-Based Genome-Editing Tools: Base Editing and Prime Editing.
Saber Sichani A; Ranjbar M; Baneshi M; Torabi Zadeh F; Fallahi J
Mol Biotechnol; 2023 Jun; 65(6):849-860. PubMed ID: 36547823
[TBL] [Abstract][Full Text] [Related]
2. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors.
Anzalone AV; Koblan LW; Liu DR
Nat Biotechnol; 2020 Jul; 38(7):824-844. PubMed ID: 32572269
[TBL] [Abstract][Full Text] [Related]
3. Prime editing in plants and mammalian cells: Mechanism, achievements, limitations, and future prospects.
Hillary VE; Ceasar SA
Bioessays; 2022 Sep; 44(9):e2200032. PubMed ID: 35750651
[TBL] [Abstract][Full Text] [Related]
4. Prime editing: Its systematic optimization and current applications in disease treatment and agricultural breeding.
Yu X; Huo G; Yu J; Li H; Li J
Int J Biol Macromol; 2023 Dec; 253(Pt 4):127025. PubMed ID: 37769783
[TBL] [Abstract][Full Text] [Related]
5. Boosting targeted genome editing using the hei-tag.
Thumberger T; Tavhelidse-Suck T; Gutierrez-Triana JA; Cornean A; Medert R; Welz B; Freichel M; Wittbrodt J
Elife; 2022 Mar; 11():. PubMed ID: 35333175
[TBL] [Abstract][Full Text] [Related]
6. Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing.
Tao J; Bauer DE; Chiarle R
Nat Commun; 2023 Jan; 14(1):212. PubMed ID: 36639728
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
8. New advances in CRISPR/Cas-mediated precise gene-editing techniques.
Richardson C; Kelsh RN; J Richardson R
Dis Model Mech; 2023 Feb; 16(2):. PubMed ID: 36847161
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in CRISPR technologies for genome editing.
Song M; Koo T
Arch Pharm Res; 2021 Jun; 44(6):537-552. PubMed ID: 34164771
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells.
Bloomer H; Khirallah J; Li Y; Xu Q
Adv Drug Deliv Rev; 2022 Feb; 181():114087. PubMed ID: 34942274
[TBL] [Abstract][Full Text] [Related]
11. Basic Principles and Clinical Applications of CRISPR-Based Genome Editing.
Lim JM; Kim HH
Yonsei Med J; 2022 Feb; 63(2):105-113. PubMed ID: 35083895
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough in CRISPR/Cas system: Current and future directions and challenges.
Ali A; Zafar MM; Farooq Z; Ahmed SR; Ijaz A; Anwar Z; Abbas H; Tariq MS; Tariq H; Mustafa M; Bajwa MH; Shaukat F; Razzaq A; Maozhi R
Biotechnol J; 2023 Aug; 18(8):e2200642. PubMed ID: 37166088
[TBL] [Abstract][Full Text] [Related]
13. Improvements in the genetic editing technologies: CRISPR-Cas and beyond.
Mingarro G; Del Olmo ML
Gene; 2023 Feb; 852():147064. PubMed ID: 36435506
[TBL] [Abstract][Full Text] [Related]
14. [CRISPR/Cas-mediated DNA base editing technology and its application in biomedicine and agriculture].
Yu C; Mo J; Zhao X; Li G; Zhang X
Sheng Wu Gong Cheng Xue Bao; 2021 Sep; 37(9):3071-3087. PubMed ID: 34622618
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research.
Li ZH; Wang J; Xu JP; Wang J; Yang X
Mil Med Res; 2023 Mar; 10(1):12. PubMed ID: 36895064
[TBL] [Abstract][Full Text] [Related]
16. Challenges in Gene Therapy for Somatic Reverted Mosaicism in X-Linked Combined Immunodeficiency by CRISPR/Cas9 and Prime Editing.
Hou Y; Ureña-Bailén G; Mohammadian Gol T; Gratz PG; Gratz HP; Roig-Merino A; Antony JS; Lamsfus-Calle A; Daniel-Moreno A; Handgretinger R; Mezger M
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553615
[TBL] [Abstract][Full Text] [Related]
17. Prime Editing in Mammals: The Next Generation of Precision Genome Editing.
Wang D; Fan X; Li M; Liu T; Lu P; Wang G; Li Y; Han J; Zhao J
CRISPR J; 2022 Dec; 5(6):746-768. PubMed ID: 36512351
[TBL] [Abstract][Full Text] [Related]
18. In vivo application of base and prime editing to treat inherited retinal diseases.
Jo DH; Bae S; Kim HH; Kim JS; Kim JH
Prog Retin Eye Res; 2023 May; 94():101132. PubMed ID: 36241547
[TBL] [Abstract][Full Text] [Related]
19. Current advances in overcoming obstacles of CRISPR/Cas9 off-target genome editing.
Aquino-Jarquin G
Mol Genet Metab; 2021; 134(1-2):77-86. PubMed ID: 34391646
[TBL] [Abstract][Full Text] [Related]
20. Tools for Efficient Genome Editing; ZFN, TALEN, and CRISPR.
Shamshirgaran Y; Liu J; Sumer H; Verma PJ; Taheri-Ghahfarokhi A
Methods Mol Biol; 2022; 2495():29-46. PubMed ID: 35696026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
